Ligand Pharmaceuticals Incorporated LGND
316.83 USD +2.67 (+0.85%)
At closeNov 11, 2026, 6:36 PM EST
317.89 +1.06 +0.33%
After hours · Nov 11, 6:36 PM ET
314.17 Day range 322.41
175.89 52-week range 326.63
- YTD
- +67.57%
- 1 year
- +51.81%
News
benzinga.com Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350 Barclays analyst Glen Santangelo maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $345 to $350.
defenseworld.net Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average…
defenseworld.net Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average…
benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $397 to $402.
seekingalpha.com Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy Ligand Pharmaceuticals earns a BUY rating, driven by robust royalty growth and the accretive XOMA acquisition. Filspari's 85% YoY royalty growth and new FSGS indication position it as LGND's leading…
benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
seekingalpha.com Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Melanie Herman - Executive Director of Investor Relations and Financial Planning &…
marketbeat.com What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired…
benzinga.com Ligand Pharmaceuticals Q3 2026 Earnings Call Transcript Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 analyst estimate. Lowers FY2026 sales outlook from $270.000 million-$310.000 million to…
benzinga.com Ligand Pharmaceuticals Q3 Adj. EPS $2.67 Beats $2.38 Estimate, Sales $78.700M Beat $77.232M Estimate Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.38 by 12.18 percent. This is a 13.59 percent decrease over earnings…
globenewswire.com Ligand Reports Third Quarter 2026 Financial Results Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance…
globenewswire.com Ligand to Participate in November Investor Conferences JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor…
benzinga.com Here's How Much $1000 Invested In Ligand Pharmaceuticals 20 Years Ago Would Be Worth Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 20 years by 12.04% on an annualized basis producing an average annual return of 20.96%. Currently, Ligand…
globenewswire.com Ligand to Host Investor Day on December 8, 2026 JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from…
globenewswire.com Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29,…
benzinga.com Here's How Much $1000 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 13.64% on an annualized basis producing an average annual return of 26.84%. Currently, Ligand…
benzinga.com Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
benzinga.com Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345 Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.- benzinga.com HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.
globenewswire.com Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a…
benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.- benzinga.com Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand…
businesswire.com Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced…
prnewswire.com Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by…
globenewswire.com Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to…- benzinga.com Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals…
seekingalpha.com Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is…
defenseworld.net Reviewing Omeros (NASDAQ:OMER) & Ligand Pharmaceuticals (NASDAQ:LGND) Omeros (NASDAQ: OMER - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
benzinga.com If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals…
marketbeat.com Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage…
globenewswire.com Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor…- benzinga.com $100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals…
defenseworld.net Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the…
benzinga.com Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330 Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.- benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.
marketbeat.com Ligand Pharmaceuticals Q2 Earnings Call Highlights Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty…
seekingalpha.com Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript- benzinga.com HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358 HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $289 to $358.
- benzinga.com Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to…
- benzinga.com $100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand…
benzinga.com Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326 Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.- benzinga.com Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and announces $387 price target.
- benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $262 to $340.
benzinga.com Why Is Agenus Stock Falling on Tuesday? Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.
benzinga.com Why Is Agenus Stock Gaining Monday? Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
benzinga.com B of A Securities Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $388 B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $266 to $388.- benzinga.com Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332 Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $255 to $332.
- benzinga.com Ligand Plans $550M Convertible Notes Offering, To Use Notes Sale for Share Buybacks and Corporate Needs Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a
benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session